NMDA receptor antagonist ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats

Psychopharmacology

Volumn 175, Issue 2, 2004, Pages 179-188

  Kelsey, John E ^a   Mague, Stephen D ^b   Pijanowski, Reyna S ^a   Harris, Ryan C ^a   Kleckner, Nancy W ^a   Matthews, Russell T ^c  

^a BATES COLLEGE   (United States)

^b MCLEAN HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

(+) MK 801; CPP; DA; L Dopa; Parkinson's disease; Rotation

Indexed keywords

4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; DIZOCILPINE; DOPAMINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; ADRENERGIC RECEPTOR STIMULATING AGENT; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG EFFECT; FOREBRAIN; MALE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RAT STRAIN; ANIMAL; BRAIN; DRUG ANTAGONISM; DRUG INTERACTION; GAIT;

ADRENERGIC AGENTS; ANIMALS; BRAIN; DIZOCILPINE MALEATE; DOPAMINE AGENTS; DRUG INTERACTIONS; GAIT; LEVODOPA; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 4544357027     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1799-5     Document Type: Article

References (36)

1. Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak P, Tolosa E et al. (1999) Levodopa in the treatment of Parkinson's disease: a consensus meeting. Move Disord 14:911-913
2. Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588
3. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88
4. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329:1021-1027
5. Carlsson M, Carlsson A (1989a) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm [Gen Sect] 77:65-71
6. Carlsson M, Carlsson A (1989b) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm [Gen Sect] 75:221-226
7. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276
8. Carroll CB, Holloway V, Brotchie JM, Mitchell IJ (1995) Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site' in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology 119:55-65
9. Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628
10. Chase TN, Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47:8122-129; discussion S129-130
11. Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:135-145
12. 1- dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist. Brain Res 512:284-290
13. Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? - case of amantadine and memantine. J Neural Transm [Parkinson's Dis Dement Sect] 7:155-166
14. Engber TM, Anderson JJ, Boldry RC, Papa SM, Kuo S, Chase TN (1994) Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats. Neuroscience 59:389-399
15. Greenamyre JT (2001) Glutamatergic influences on the basal ganglia. Clin Neuropharmacol 24:65-70
16. Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18:925-964
17. Kirik D, Rosenblad C, Björklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152:259-277
18. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28:539-546
19. Klockgether T, Wüllner U, Steinbach JP, Petersen V, Turski L, Löschmann P (1996) Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 301:67-73
20. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J Neural Transm [Parkinson's Dis Dement Sect] 3:203-213
21. Mele A, Wozniak KM, Hall FS, Pert A (1998) The role of striatal dopaminergic mechanisms in rotational behavior induced by phencyclidine and phencyclidine-like drugs. Psychopharmacology 135:107-118
22. Metz GA, Whishaw IQ (2002) Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance. Neuroscience 111:325-336
23. 2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 182:611-612
24. 2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 260:402-408
25. Nash JE, Hill MP, Brotchie JM (1999) Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol 155:42-48
26. Olsson M, Nikkhah G, Bentlage C, Björklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863-3875
27. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, New York
28. Popoli P, Pèzzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L, Fuxe K, Ferrè S (2001) The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25:505-513
29. Rodriguez MC, Obeso JA, Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44:8175-188
30. Schallert T, Norton D, Jones TA (1992) A clinically relevant unilateral rat model of parkinsonian akinesia. J Neural Transm Plastic 3:332-333
31. Skuza G, Rogoz Z, Quack G, Danysz W (1994) Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. J Neural Transm [Gen Sect] 98:57-67
32. St-Pierre JA, Bédard PJ (1994) Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model. Brain Res 660:255-260
33. 2 agonist apomorphine. J Neural Transm [Parkinson's Dis Dement Sect] 6:215-226
34. Starr MS, Starr BS, Kaur S (1997) Stimulation of basal and L-dopa-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci Biobehav Rev 21:437-446
35. Tillerson JL, Cohen AD, Philhower J, Miller GW, Zigmond, MJ, Schallert T (2001) Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 21:4427-4435
36. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493